Quotient Clinical has acquired formulation development specialist Co-Formulate Limited
Quotient Clinical has developed a translational pharmaceutics platform, which integrates formulation development, real-time GMP manufacturing and clinical testing.
The acquisition of Co-Formulate will reinforce and extend Quotient’s existing pharmaceutical development capabilities across solid, semi-solid and liquid formulations according to Quotient.
Mark Egerton, chief executive officer of Quotient Clinical, said: “We are delighted that Co-Formulate has become part of our business. The company brings a wealth of formulation development experience in areas that complement our existing capabilities.
“Its expertise in helping customers to manage product life cycles and develop a range of product formats, including age-appropriate paediatric and geriatric formulations, will help us to extend our customer base and service portfolio.”
Huw Jones and Nazim Kanji, directors and founders of Co-Formulate, said: “We are excited to join forces with Quotient Clinical. We will now be in a position to deliver seamless programs consisting of formulation development, clinical trial manufacturing and clinical testing, all under the umbrella of a single organisation.”
Financial terms of the transaction were not disclosed.